Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160370 | 0.84 | CA12 (0.53) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL7285824 | 0.83 | NOD2 (0.46) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL5125297 | 0.83 | KDM4E (0.45) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL7884252 | 0.83 | ALDH1A1 (0.48) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL7884857 | 0.82 | KMT2A (0.47) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL7877726 | 0.81 | MAPT (0.45) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL17868857 | 0.81 | NOD2 (0.41) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL13986463 | 0.80 | SMN1; SMN2 (0.43) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL3296461 | 0.80 | NOD2 (0.59) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL689437 | 0.79 | MCL1 (0.56) | KDM4ESMN1; SMN2CYP1A2RXFP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109153643-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2022-06-21 | — | — | CN | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| CN-109988151-B | Acetylene compound, preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2021-04-23 | — | — | CN | disclosed |
| EP-3423435-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885CRHBP 2815/4885CRHR2 4384/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885CRHBP 2815/4885CRHR2 4384/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885CRHBP 2815/4885CRHR2 4384/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885CRHBP 2815/4885CRHR2 4384/4885 |
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | KDM4E 2963/4885CRHBP 2003/4885CRHR2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.